Access and SpePharm Announce Licensing of MuGard for Europe
SpePharm Will Market MuGard in Europe for the Treatment of Oral Mucositis
Access Pharmaceuticals, Inc. and SpePharm Holding, B.V. announced the signing of a definitive licensing agreement under which SpePharm will market Access's product MuGard in Europe.
MuGard is Access' proprietary product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. MuGard has received marketing allowance in the United States from the Food and Drug Administration under a 510(k) procedure. SpePharm will be responsible for marketing MuGard throughout the European Union plus Switzerland, Norway and Iceland, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory.
In connection with the exclusive Licensing Agreement, SpePharm will pay Access an upfront fee and substantial royalties on net sales.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.